Pharma Journalist

Multi-Functional Cell Therapies Summit
2021-05-04 - 2021-05-06 | EST | Digital
Advance Cutting-Edge Research and Development with Next-Generation Cell Therapies, to Deliver Best-in-Class Products to Patients in Need
Cell therapies hold life-saving potential for patients, and the race is on to develop best-in-class, living, ‘thinking’ drugs. Relapse rates and barriers to solid tumor efficacy mean the cell therapy industry must innovate, now more than ever.
The inaugural Multi-Functional Cell Therapies Summit gathers the avantgarde to discuss strategies to weaponize cell therapies with antigenic, engineered and combination approaches to create sophisticated, multi-functional systems.
For more details about the program, speaker faculty or pricing and discounts, download the brochure.

Chronic Hepatitis B Drug Development Summit
2021-05-05 - 2021-05-06 | Virtual Summit
The first ever meeting purpose-built for discussing the advancement of curative therapies for chronic HBV infection.
Featuring an all-star speaker faculty from across industry, NGOs and academia, all dedicated to finding a curative therapy for Chronic HBV infection. This is a unique opportunity to review the latest clinical investigations with novel and classic therapeutics including RNAi and immuno-therapies.

Here is just a snapshot of some of the speakers who are joining us:
Yuchun Nie, Senior scientist, Aligos Therapeutics
Gaston Picchio, Chief Development Officer, Arbutus Biopharma
William Delaney, Chief Scientific Officer, Virology, Assembly Biosciences (USA)
Stephane Daffis, Scientist II, Gilead Sciences
Patricia Mendez, Vice President – Clinical Development, Immunocore Ltd
Andrew Vaillant, Chief Scientific Officer, Replicor Inc.
Tom Evans, Chief Scientific Officer, Vaccitech
David Anderson, Chief Scientific Officer, VBI Vaccines Inc.
Don’t miss out on this opportunity to benchmark yourself against the competition, get a comprehensive update on how the field stands and network with peers from across the field at the inaugural Chronic Hepatitis B Drug Development Summit. Find out more >> https://ter.li/haruyt

SMi’s 5th Annual Highly Potent Active Pharmaceutical Ingredients Conference (HPAPi)
2021-05-10 - 2021-05-11 | Online Access Only
Innovations in HPAPI Containment & Facility Design for Successful Manufacturing
Sponsored by: Catalent Pharma Solutions and FPS Food and Pharma Systems
Chaired by: Justin Mason-Home, Director, HPAPI Project Services Limited
SMi is delighted to announce its 5th Annual Highly Potent Active Pharmaceutical Ingredients Virtual Conference on 10th and 11th May 2021.

Highly Potent Active Pharmaceutical Ingredients (HPAPIs) play an increasing central role in the fight against many diseases. There is an increasing need to protect workers who handle HPAPIs along the life cycle of the drug product manufacturing, from synthesis of the pharmaceutical active ingredient to distribution of the finished medicinal product. This year’s event will focus on 4 key themes: best practices for toxicological assessment, innovations in containment and facility design, advances in the use of robotics and automation in manufacturing processes, and environmental considerations. Key case studies will be highlighted throughout these themes, revealing the key challenges for current HPAPI manufacture, and insights into the latest technological and regulatory advances in this increasingly potent environment.
Attend the conference and join our networking platform for industry professionals to provide you with the expertise to overcome the challenges of the HPAPi industry.
Key Speakers for HPAPi include:

Ester Lovsin-Barle, Head of Product Stewardship and Health, Takeda
Richard Denk, Senior Consultant Aseptic Processing & Containment, SKAN AG
Raphael Nudelman, Director of Chemical & Computational Toxicology, Teva Pharmaceutical
Olindo Lazzaro, Director Global EHS, AbbVie
Fred Ohsiek, Senior Specialist, Cleaning Validation, Novo Nordisk
Florian Grundmann, MSAT Team Lead, Cleaning Validation, Roche
Ildiko Ziegler, QA Manager, Vanessa Research
Jack Brown, Senior Research Fellow, formerly Boehringer Ingelheim
Reinhold Maeck, Head of Corp EHS Regulatory Intelligence, Boehringer Ingelheim

Doreen Parrish, Head of Corporate Audit, Global EHS, Takeda
Key Reasons to Attend HPAPi:

Explore best practices in hazard assessment and occupational toxicology
understand strategic considerations for planning pilot plants and scaling up manufacturing capabilities for high potency compounds
discover potential for automation and robotics in pharmaceutical manufacturing and technologies for protecting operators from hazardous substances
discuss the opportunities for effective CDMO relationships and explore methods for strengthening those partnerships
Delve into the expanding ADC market within and beyond oncology
Virtual conference benefits include virtual exhibition booths packed with information, networking features to chat and share contact details with attendees

View the full agenda: www.highlypotentapi.com/PJwl

SMi’s 21st Annual Pain Therapeutics Conference
2021-05-10 - 2021-05-11 | Virtual Conference – Online Access Only
Sponsored by: MD Biosciences and Transpharmation
Chaired by Michael Scherz, Founder & CEO, Metys Pharma and Naheed Mirza, Early Development Pain & CNS Specialist
Explore Cutting Edge Drug Discovery Science and Key Clinical-Stage Pain Therapies in the Pipeline
SMi’s 21st Pain Therapeutics Conference will focus on looking into research within pain therapeutics. In particular, the long-term (HEAL) initiative will be discussed and its role in advancing research to reduce the risks of opioid use and misuse and improve pain management, thereby reducing reliance on opioids and the national opioid public health crisis. Talks will also address the importance of sex, gender and race in pain research, including biomarkers, molecular targets, clinical and experimental models of pain.

The conference also address cutting edge drug discovery science, preclinical development trends, analysis of key clinical-stage pain therapies, with a focus on highlighting the importance of biomarker discovery and its contribution to early stage studies on pain. This will be topped off with a panel debate on rethinking pain clinical trials during the COVID-19 pandemic. And further look into treating painful osteoarthritis of the knee with a novel anti NGF, anti-TNFα bispecific fusion protein as well as therapeutic novelties signifying a paradigm shift in migraine prevention. Additionally, the conference will explore Botulinum neurotoxin, Sigma 1 proteins and AP-325 as novel treatment for neuropathic pain as well as the high unmet medical need to develop a novel non-drowsy skeletal muscle relaxant and explore pain genetics in rare diseases as well as the Opioid Crisis and the future of addiction and Pain Therapeutics.
Join Europe’s leading Pain Therapeutics Virtual Conference in May 2021 to explore cutting edge drug discovery science and key clinical-stage pain therapies in the pipeline, bringing together leading pharmaceutical companies and to discuss solutions for the challenges of clinical trial design and conduct.
#SMiPain
Key Reasons to Attend the Conference:

Discover which innovative new therapies are driving clinical development including case studies from Novaramed and Vapogenix
Examine the best strategies to generate more funding in pain research clinical trials to eliminate the issue of underfunding
Explore how COVID-19 has changed the experience of clinical trials and presented an opportunity to reform the way we approach data verification, data analysis and data collection
Understand the role of biomarkers in evaluating target engagement of new drugs and predicting analgesic efficacy
Virtual Conference Benefits include virtual exhibition booths packed with information, networking features to chat and share contact details with other attendees, and virtual meetings and networking socials.

WHO SHOULD ATTEND
Chief Executive Officer, Chief Scientific Officers, Chief Medical Officers, Managing Directors, CEO, Head of Department, Principal Research Scientists, Clinical lead, Clinical Operations in the following fields:

Pain and Migraine
Inflammation
Chronic Pain
Neuropathic Pain
Analgesic pre-clinical development
Anaesthesia and Pain Management
CNS clinical trials
Ion Channel Pharmacology
Pharmacology Intelligence
Translational science
Drug development
Exploratory development

View the full agenda: http://www.pain-therapeutics.co.uk/PJwl

Manufacturing Assets and Facility Management in Pharma Summit 2021
2021-05-11 - 2021-05-13 | Virtual Conference
Manufacturing Assets and Facility Management in Pharma Summit returns in 2021. Taking place virtually this May 11-13, a must attend event to help modernize your facility and revitalize your asset management strategies. Join this cutting-edge discussion and network with engineering, maintenance and manufacturing facilities leaders.
To know more about Manufacturing Assets and Facility Management in Pharma Summit 2021 please click here.

Injectable Drug Delivery 2021
2021-05-12 - 2021-05-13 | St. James’ Court, 54 Buckingham Gate, Westminster, London, SW1E 6AF, United Kingdom
Assessing the innovations in formulations and devices for enhanced injectable delivery
SMi Group is pleased to announce the third annual Injectable Drug Delivery conference, which will be held in London on the 12th and 13th May 2021.
Part of Europe’s leading Injectable conference series, Injectable Drug Delivery will assess innovations in drug product formulation and biologics, innovations in device design, quality management and connectivity for enhanced subcutaneous delivery.

With rapid developments in the parenteral space, the injectable drug delivery market is set to reach USD 902.3 billion by 2027, with an increased focus on patient centricity during DDC development and innovations in device development, including new therapeutic applications such as the delivery of siRNA. This year’s event will focus on advances in drug product formulation and innovations of device design and development to aid delivery.
Furthermore, the conference will assess the evolving regulatory environment of injectable drug delivery with industry and regulatory representatives presenting updates on current guidelines.
The two-day agenda also offers peer-to-peer networking with Global Product Managers, Device Testing Managers, Senior Device Engineers, Heads of Device Development, Heads of Formulation and Drug Process Development, and many more.
The benefits of attending:
This conference offers a chance to learn about innovative injectable drug delivery systems with industrial insights on the following:

DELVE into the latest work in complex formulation for subcutaneous delivery
BENCHMARK against leading pharma companies working to enhance device design and development
UNDERSTAND the regulatory environment of the injectables space from leading regulatory and industry advisors
ENGAGE in industry case studies on design controls, human factors and parenteral formulation
EXPLORE advances in connectivity and human factors key learnings in two pre-conference workshops

Who should attend:
Executives, Directors, VPs, Heads, Principals, Managers, Scientists, Researchers of:

Autoinjectors
Wearables
Device Engineering
Human Factors
CMC
Injectables
Sterile Manufacturing
Packaging
Regulatory Affairs

Featured Speakers:

Alexander Zuern, Device testing manager, Novartis International AG
Andrew Warrington, Project Leader & Patient Advocate, Novartis
Benjamin Werner, Scientist, Boehringer Ingelheim Pharma GmbH & Co. KG
Bjorg K Hunter, Regulatory Manager, Devices, GSK
Blake Green, Senior Manager Regulatory Affairs, Amgen
Camille Dagallier, Formulation and Drug Process Development Senior Scientist, Sanofi
Christopher Muenzer, Senior Device Technology Manager, Novartis
Joel Richard, Head of Technical & Pharmaceutical Operations, MedinCell
Mark Palmer, Scientific Leader, Biopharm Device Engineering, GSK
Rebecca Moses, Director, Core Human Factors Inc.
Rupal Nguyen, Principal Engineer, Allergan
Stefania Ragone, Pharmaceutical Assessor, Medicines & Healthcare Products Regulatory Agency (MHRA)
Tina Arien, Principal Scientist, Janssen Pharmaceutica
Vikas Jaitely, Director, Global Regulatory Affairs Transitional Medicine and Devices, Merck

LinkedIn: @SMi Pharma
Twitter: @SMiPharm #SMiInjectables

Genetic Vaccine Development for Infectious Diseases Summit
2021-05-18 - 2021-05-20 | Online
The COVID-19 pandemic brought life-changing disruptions to people around the world and has turned the typical vaccine R&D process on its head. A combination of urgent need, unprecedented investments, and advances in genetic engineering has allowed what was once mere speculation to become not only our reality, but our future.

With pandemic vaccines now launching at record speeds, the first Genetic Vaccine Development for Infectious Diseases Summit will focus on overcoming the translational and clinical challenges of developing genetic vaccines targeting infectious diseases, including Influenza, Lassa fever, Ebola, MERS, HIV, Zika, and COVID-19.
With a focus on mRNA, DNA, and engineered viral vector-based vaccines, this niche 3-day agenda has been specifically designed to help industry experts to discuss new genetic-based vaccine platforms, preclinical and clinical case studies, optimized delivery methods, and the future of vaccine R&D to usher in a new era of vaccinology, with experts from BioNTech, Pfizer, Moderna, AstraZeneca and CureVac.
To know more about Genetic Vaccine Development for Infectious Diseases Summit please
click here.

5th Annual MarketsandMarkets Bioprocessing of Biotherapeutics-UK,EU & APAC-Virtual
2021-05-20 - 2021-05-21 | Virtual Event
After the successful four editions of Bioprocessing of Cell therapies, coming up with 5th Annual of Bioprocessing of Biotherapeutics brings together leading bioprocessing scientists to share day-to-day challenges and practical solutions for the development, manufacture and quality of protein expressions, cell, and gene therapies.
The virtual event will present detailed case studies and interactive discussions in cell culture, scale-up, continuous processing, recovery, purification, process and product characterization, and formulation.
Event Website: https://events.marketsandmarkets.com/5th-annual-marketsandmarkets-bioprocessing-of-biotherapeutics-uk-eu-apac-virtual/
Registration link: https://events.marketsandmarkets.com/5th-annual-marketsandmarkets-bioprocessing-of-biotherapeutics-uk-eu-apac-virtual/register

Ligase Targeting Drug Development – Digital Summit
2021-05-25 - 2021-05-27 | Digital Event
As the therapeutic value of manipulating previously hard-to-drug ubiquitin ligases becomes more and more evident in addressing numerous diseases with unmet clinical needs, the inaugural Ligase Targeting Drug Development Summit arrives as the dedicated scientific and networking forum for large pharma, innovative biotech and research institutes to seize the day.

Built with large pharma and biotech insight, the Ligase Targeting Drug Development Summit is fully dedicated to enabling novel ligase discovery and characterization, achieving cell and tissue specificity and expanding chemical biology tools to therapeutically leverage ubiquitin ligases for effective protein modulation or degradation strategies.
As leading pharma companies join forces to bridge the gap between the functional knowledge and true translational value of ubiquitin ligases and their associated ligands, join us to advance your understanding, differentiate your pipelines and tap into the uncapped therapeutic potentials of this emerging field.
To know more about Ligase Targeting Drug Development – Digital Summit please click here.

Gene Therapy for Muscular Disorders
2021-05-25 - 2021-05-27 | Virtual Event
With clinical holds lifting there has been more investment and clinical progress in the gene therapy for muscular disorders space than ever before, yet the consequences of toxicity are not a distant memory. Despite the successes, there are still withstanding challenges for gene therapy developers targeting the muscle when it comes to optimizing delivery and navigating toxicity to develop truly safe and transformative therapeutics for muscular disorders patients.

The first industry-dedicated Gene Therapy for Muscular Disorders Summit will focus on overcoming the translational and clinical challenges of developing genetic therapies targeting muscular disorders, including Duchenne Muscular Dystrophy (DMD), Limb-Girdle Muscular Dystrophy (LGMD), Pompe Disease and X-Linked Myotubular Myopathy.
With a focus on AAV and gene editing technologies and insights from Pfizer, Solid Biosciences, Audentes and Vertex, this niche 3-day agenda has been specifically designed to help industry experts to:

Optimize your promoter choice and navigate IP challenges for more efficient delivery to muscular targets
Discover the next generation capsids being developed for improved muscle selectivity and reduced immunogenic responses
Understand the biology of different immunogenic responses and hear feedback from trialled strategies to ensure optimal patient safety
Hear the latest research in muscular disorder biomarkers
Define clinically meaningful muscular endpoints to successfully and objectively measure muscular disease improvement
Tackle regulatory challenges to demonstrate gene therapy durability
Overcome clinical challenges to manage patient heterogeneity for patient centric and meaningful trials

Join your peers to share, learn and discuss at the first industry-focused Gene Therapy for Muscular Disorders. Overcome your immunogenicity challenges and mitigate toxicity with high doses targeting the muscle to successfully demonstrate durability with your gene therapy product.
To know more about Gene Therapy for Muscular Disorders please click here.

3rd Microbiome Movement – Maternal & Infant Health Summit 2021
2021-05-25 - 2021-05-27 | Virtual/Online
Harness the Maternal-Infant Microbiome, Establish New Mechanisms of Action, and Develop Breakthrough Health Products that Proactively Prevent Disease Risk
Returning for another year, this platform will unite industry and academics in the exploration of preventative and therapeutic treatment of the microbiome during pregnancy and early life. The discussion during this 3-day conference will cover key periods of pregnancy, birth and infant development to encompass a range of areas where therapeutic, nutritional targeting and research can be undertaken.
Take this opportunity to join the event and you can:

Gain a complete understanding of the current research and therapeutic opportunities as we walk through the infant journey from in utero development through to the first 1000 days
Understand the value of the mother’s experience and health for foetal development with talks from Siobhain O’Mahony and Mary Claire Kimmel
Discover new therapeutic research into the vaginal microbiome, such as PhagoMed and Columbia University
Build a broader understanding of the benefits of prevention with Evolve Biosystems highlighting cost-saving from early life treatments and the NIH’s push to advance this area of science
Hear from Siolta Therapeutics and ParetoBio in developing therapeutic treatments for allergies

Join us to further your understanding of how cutting-edge science is helping establish a causal relationship between the maternal-infant microbiome and long-term health effects, and how this can be translated to demonstrate clinically validated solutions.
To know more about 3rd Microbiome Movement – Maternal & Infant Health Summit 2021 please click here.

STING & TLR-Targeting Therapies Summit
2021-05-25 - 2021-05-27 | Digital Event
This is the definitive drug development forum for research teams to investigate how to modulate the cGAS-STING and Toll-like receptor (7/8/9) pathways both as monotherapies and as adjuvants in combinatorial approaches.
This meeting comes at a critical point for the cancer immunotherapy field, as researchers look to increase patient response rates and the efficacy on checkpoint inhibitors in several solid tumor indications. Preclinical and early clinical data for modulators of the STING & TLR plus other innate immune checkpoint inhibitors has been hugely promising.

Use this key forum to hone your innate immune activation strategies and deliver safe and effective treatments through systematic and intra-tumoral administration which can stimulate the adaptive immune arm, counteract solid tumor-induced immunosuppression and increase response to checkpoint inhibitors.
View the event guide for the full agenda!
Innate Immune Checkpoints & Activation Pre-Focus Day
In addition to two full conference days to STING/TLR-targeting, there will be a pre-focus day specifically on innate immune checkpoints and the activation of specific cell types including natural killer cells, macrophages and myeloid-derived suppressor cells.
An executive speaker faculty will take you through the leading drug candidates aimed at inhibitory and activation receptors on key cellular component of the innate immune system.
View the full event guide for more information.

Gene Therapy Analytical Development Europe
2021-05-25 - 2021-05-27 | Virtual
In the context of unprecedented gene therapy investment and clinical progress, with mounting regulatory scrutiny, Gene Therapy Analytical Development Europe will unite innovative biotech and pharma organisations to develop robust analytical tools to guarantee the consistency, quality, and safety of gene therapy products.

Whether you’re looking for specific characterisation, potency or infectivity approaches to improve your current analytical toolbox or if you’re seeking to understand how gene therapy analytics differ from other biologics you’ve worked on in the past, this focused, technical event will provide insights specifically on the unique analytical challenges posed by gene therapy vectors, delivered by ‘boots on the ground’ scientists grappling with these challenges first-hand.
Join 150+ analytical pioneers to discover the realities of working with tools like dPCR, AUC and HPLC, as well as how and where these tools can be most effective in process development, and what the European regulators expect in order to grant approval. Whether you’re working with AAV or lentiviral vectors, this is your opportunity to enhance your existing analytical methods and explore innovative new tools to support safe and effective gene therapy development.
To know more about Gene Therapy Analytical Development Europe please click here.

Inner Ear Disorders Therapeutics Summit – Digital Event
2021-05-25 - 2021-05-27 | Digital Event
Hearing loss has a huge impact on the quality of life for millions of people, and as the average age of the population increases, the need for curative life-changing therapies targeting hearing loss and inner ear disorders has never been more important.

The Inner Ear Disorders Therapeutics Summit is gathering the world’s leading biopharmaceutical companies and KOLs at the only industry-focused summit dedicated to the translation and clinical development of novel gene therapy, cell therapy and small molecule-based approaches to treat inner ear disorders, with the aim to progress the industry towards the first clinically approved therapy.
Join industry and academic experts to discuss the best preclinical modelling approaches for translative proof of concept data, identify the most appropriate biological endpoints and overcome the major challenges to develop safe, effective, and clinically viable inner ear disorder therapies to address the unmet medical need.
To know more about Inner Ear Disorders Therapeutics Summit please click here.

TCR-based Therapies Summit
2021-06-08 - 2021-06-10 | EST | Digital
The TCR-based Therapies Summit is Dedicated to Supercharging TCR Design, Translation & Manufacturing Strategy for Solid Tumor Success
Running digitally for 2021, the 2nd TCR-based Therapies Summit is the leading industry-focused meeting dedicated to supercharging the expanded TCR repertoire through enhanced target specificity, density & binding affinity for solid tumor indications.

This June (8-10), join this exclusive community online to virtually network and learn from the leading experts in pharma, biotech and academia, as we discuss how to how to overcome on-target off-tumor toxicity, enhance the binding affinity and avidity of TCR-T therapies and utilize dual targeting and combination approaches for enhanced efficacy.
Navigate across 3 days packed with dedicated, interactive formats exploring the identification of novel targets, the importance of safety profiling, and discuss optimization of soluble approaches for the development of next-generation TCR-T products.
For more details about the program, speaker faculty or pricing and discounts, download the brochure.
Helping Deliver Best-In-Class TCR Therapies
Join experts as they discuss the design, efficacy and clinical development of TCR therapeutics for solid tumor indications and beyond.

Optimizeyour TCR therapy approach
Explorenovel combination strategies
Armyour cells against the hostile tumor microenvironment
Improvetarget selection and off-target validation
Explorethe future of manufacturing for next-generation TCRs

“Hanson Wade’s CAR-TCR summit has been already the leading specialized conference in the field – what a great suggestion to set up a dedicated forum for the rapidly growing TCR-T area.”
Steffen Walter, Chief Scientific Office, Immatics US

Next Generation Gene Therapy Vectors
2021-06-08 - 2021-06-10 | Virtual Event
The inaugural Next Generation Gene Therapy Vectors meeting is dedicated to overcoming the current immunogenicity, toxicity and manufacturability challenges facing the field by pioneering the next generation of superior delivery vectors.

Industry pioneers from cutting edge biotechs and world-leading academic vectorology groups including Dyno Therapeutics, 4D Molecular Therapeutics and Generation Bio will share how ever-increasing clinical experience is guiding strategies to decrease the immunogenicity of vectors to allow durable transgene expression, engineer vectors with lower toxicity at higher doses and use innovative technologies to optimise capsid, transgene, and promoter design.
Everything in gene therapy starts with the vector, so join this definitive, niche, digital conference to delve into the details of vector design, engineering, and optimization case studies, equipping you with the insights required to deliver transformative therapeutics to patients more effectively and safely than ever before.
To know more about Next Generation Gene Therapy Vectors please click here.

9th PREDiCT: Tumor Models Cell Therapy Summit
2021-06-13 - 2021-06-15 | Virtual Event
With commitments to advancing your preclinical and translational oncology research, we are delighted to bring the 9th annual PREDiCT: Tumor Models Cell Therapy Summit to your screens in July.
See best-in-class tumor models and how they can be effectively utilized to model the tumor microenvironment and further your MoA understanding for new cell therapies.
Learn to improve your translational and clinical confidence through the use of models to answer critical safety and efficacy questions, predict toxicity and optimize dosing for patients.
Whether you work in early discovery or late development, there is something for all non-clinical professionals with two dedicated tracks: one focused on preclinical modelling and one looking at translational studies.
Below are a few highlights you won’t want to miss!

Novartisshare how to use a simple xenograft model to effectively assess CAR-T efficacy
AstraZenecashows how to guide innovative clinical trials for cell therapies using preclinical data
Takedadiscuss how to leverage single-cell analytics to understand the complexities of the tumor microenvironment
Harvard Medical Schoolshare how they use multiple tumor models to advance NK cell therapies

Get involved! Our scientific poster sessions will be returning this year so you can share your latest advances and be apart of the conversation.
To know more about 9th PREDiCT: Tumor Models Cell Therapy Summit please click here.

Pre-Filled Syringes West Coast
2021-06-14 - 2021-06-15 | Hyatt Regency Mission Bay, 1441 Quivira Road, San Diego, CA, 92109, United States
SMi are proud to announce the 5th annual conference:
Pre-Filled Syringes West Coast 2020
14-15 June 2021
San Diego, CA, USA
Hyatt Regency Mission Bay
www.prefilled-syringes-westcoast.com/pjwl
Assessing Device Development and Regulation for Advanced Innovation
SMi is proud to present the 5th Annual Pre-Filled Syringes West Coast Conference in San Diego on 14th and 15th June 2021.

Following the success of the last event, the Pre-Filled Syringes West Coast conference is back to uncover the latest innovations in combination product development, device design, human factors engineering and drug product formulation to give a holistic overview of the industry and what we can expect for the future.
With the global market for prefilled syringes estimated to exceed $9.7bn by 2025, this year’s agenda will encompass key drivers and hot topics of the industry including; updates to regulatory guidance from industry experts and regulatory bodies, case studies on device design and complex formulation, life cycle and control strategies, and innovations in connectivity and digital health.
This two-day agenda offers you peer-to-peer networking with Global Product Managers, Senior PFS Engineers, Device Testing Managers, Heads of Late-Stage PFS Development and many more.
PLUS, two interactive post conference workshops:
Workshop A: Connected devices and digital health: How to navigate the US FDA usability engineering requirements
Hosted by Shannon Clark, Principal, UserWise, Inc.
Workshop B: Postmarket safety reporting: The current regulatory environment with a global impact
Hosted by Khaudeja Bano, Sr. Medical Director, Abbott Molecular
Key Reasons to Attend:

Engage in case study presentations from leading pharma and biotech companies on complex product formulation and optimising device design to aid delivery
Discuss show to optimise current processes to align with global regulatory updates
Delve into human factors engineering best practices
Uncover how industry is incorporating connectivity and digital health to optimise the user experience

Who should attend:

Drug-delivery developers
Medical Device Engineers
Primary Packaging material designers
Secondary packagers
Smart device developers
Training device developers
Device-safety solution providers
Drug developers

Early bird deadlines:

Register by 28th February to save $400
Register by 31st March to save $200
Register by 30th April to save $100

To register or for more information visit: www.prefilled-syringes-westcoast.com/pjwl
SOCIAL MEDIA HANDLES
Twitter: @SMiPharm #Smipfsusa
LinkedIn: follow our company page – search ‘SMi Pharma’

2nd RNAi-Based Therapeutics – Digital Summit
2021-06-15 - 2021-06-17 | Digital Event, EDT
As investments and collaborations hit a record high, the RNAi therapeutics industry continues to rapidly expand. With RNAi drugs prevailing as a therapy with huge potential against liver diseases, exciting efforts have now turned to a wide range of other diseases, from CNS, oncology, metabolism and more. Despite the growing momentum, much needs to be addressed in terms of targeted delivery, safety, and efficiency to fully unleash the therapeutic value of RNAi drugs.

Built with large pharma and pioneering biotech insights, the 2nd RNAi- Based Therapeutics Summit returns virtually in 2021 to reunite key stakeholders of the field to tap into the full therapeutic opportunity of a wide-range of targeted RNAi therapies with enhanced endosomal escape, extrahepatic delivery, & PKPD for CNS, oncology & beyond.
With a number of RNAi based clinical candidates emerging and excitement building in the field, join the 2nd RNAi Based Therapeutic Summit 2021 – the comprehensive industry guide for senior biopharmaceutical leaders from discovery, translation & clinical development functions to stay ahead of the race in developing the first targeted extrahepatic RNAi therapy that addresses unmet patient need.
To know more about 2nd RNAi-Based Therapeutics please click here.

Skin Microbiome Summit
2021-06-16 - 2021-06-17 | Park Plaza Westminster Bridge 200 Westminster Bridge Rd, Bishop’s London, SE1 7UT, United Kingdom
Skin microbiome products have been gaining more momentum in the last few years with more brands starting to develop products, and personal care giants either starting to develop their own product or investing in start-ups focusing on these. It is a very exciting time for companies looking into this at the moment, figuring out not only product development & formulation but also marketing strategy to raise more attention to this type of products. Despite huge popularity and early success stories, there is still a need to learn more on topics such as: defining the skin microbiome, formulating products, cosmetics & pharma claims, regulation for novel products, latest advances in terms of mapping & profiling technologies, as well as product testing.

ACI’s Skin Microbiome Industry Summit, taking place on the 16th & 17th June 2021 in London, will bring together the key actors of the industry to help the industry learn from one another, work together to further grow and create new business opportunities.
During the 2 days conference, the participants will enjoy the various case studies presentations, panel discussion, Q&As and networking breaks to get the industry to thrive together.
Join us in London for a highly interactive & informative conference, whilst enjoying the networking opportunities with your peers.
Members are entitled to a special discount on registration – to claim please contact Adamantia (Mado) Lampropoulou on MLampropoulou@acieu.net or +44 (0) 203 141 0607 quoting SSMe1MKTG.

Pharmaceutical Microbiology West Coast
2021-06-17 - 2021-06-18 | Hyatt Regency Mission Bay Hotel, 1441 Quivira Road, San Diego, CA, CA 92109, United States
SMi’s 4th Pharmaceutical Microbiology West Coast Conference
Novel approaches and best practices for tackling current industry contamination control challenges
SMi’s 4th Annual Conference Pharmaceutical Microbiology West Coast
NEW DATE: June 17 – 18, 2021
Location: Hyatt Regency Mission Bay Hotel, San Diego, CA, USA
Website: http://www.pharma-microbiology-usa.com

SPONSORED BY: Associates of Cape Cod, bioMérieux, Bioscience International, Microcoat, Millipore Sigma and Mettler Toledo
Co-chairs Jim Polarine, Senior Technical Service Manager, STERIS Corporation & Geeta Singh, Plant and Network Technical Specialist III, Genentech
Following on the success of the last West Coast event, SMi proudly presents the 4th Pharmaceutical Microbiology West Coast Conference, in San Diego, USA, on June 17th and 18th 2021 bringing microbiology experts to focus on innovations in rapid methods and contamination control strategies. Microbes such as bacteria, fungi, parasites and viruses that can contaminate current and novel pharmaceutical products or therapies may stem from various sources such as raw materials and human operators, are taken into consideration.
This concern is critical in advanced products/therapeutics facilities where often distinct areas within manufacturing are slowly merging, providing potential new sites for contamination events. The conference showcases sessions that cover alternative endotoxin testing and rapid mycoplasma testing as well as implementation of in-line biodurden monitoring to control water systems, to name a few. Due to the complexities brought about by more advanced therapeutic products, both drugs and patients are time dependent and rapid methods are ever more desired.
A significant portion of the conference will focus on contamination control strategies and facilities support/novel technologies such as a look at a sustainable global contamination control program, cleanroom pass thru best practices and a case study executing rapid transition from clinical to commercial manufacturing and more. Also see a regulatory session discussing objectionable organisms in non-sterile drug products and an all-women panel discussion: ‘culturing’ successful women microbiologists.
Event Hashtag: #SMiPharmaMicroWC
KEY HIGHLIGHTS FOR 2021 INCLUDE:

Discuss the guidance, regulations and case studies for objectionable organisms in non-sterile drug products from ValSource, Inc.
Gain insight into changing paradigms – moving to in-process testing from Johnson & Johnson
Examine alternative endotoxin test methods for products exhibiting LER from Amgen
Explore how to effectively scale up from clinical to commercial in three moves from Bristol-Myers Squibb
Join us for our first All-Women Panel Discussion on ‘Culturing’ successful women microbiologists

Plus a half day interactive workshop on Wednesday, June 16th 2021:
Afternoon Workshop: Data Integrity in Environmental Monitoring: Causes and Solutions
Led by: Ziva Abraham, CEO, Microrite and Morgan Polen, SME, Cleanroom Contamination Control Expert, Microrite
View the full agenda: http://www.pharma-microbiology-usa.com
WHO SHOULD ATTEND
Senior Microbiologist, Lead Scientist, Laboratory Manager, QA Specialist Drug Substance External Manufacturer, Business Development Manager – Testing, Pharmaceutical Microbiology Consultant, Higher Pharmacopoeia Scientist, Analytical Standards Specialist
SOCIAL MEDIA HANDLES
Twitter: @SMiPharm
Event Hashtag: #SMiPharmaMicroWC
LinkedIn: follow our company page – search ‘SMi Pharma’
ADDITIONAL CONTACT INFO
Simi Sapal – Marketing Manager
Pharmaceutical Division – SMi Group Ltd
T: +44 (0)20 7827 6100
E: ssapal@smi-online.co.uk

6th Annual Oncolytic Virotherapy Summit
2021-06-17 | Westin Copley Place, 10 Huntington Ave, Boston, MA, MA 02116, United States
In its most exciting year yet the field of oncolytic virotherapy has seen the highest number of clinical read-outs, the emergence of next generation viruses, and never-before-seen combination therapies.
Now in its 6th year, the Oncolytic Virotherapy Summit is the industry’s definitive guide to turning viral vehicles into clinically effective therapeutics across oncology indications. With 3 days of in-depth cutting-edge case studies and the highest caliber of industry discussions, The OV Summit will provide the roadmap to oncolytic virotherapy market success.

Uncover fresh studies from pharma and biotech companies of all sizes, as well as clinicians and leading academics for a complete picture of the current challenges and opportunities.
This year’s Summit will help you to:

Understand how viral backbone modification can achieve intravenous delivery
Harness carefully selected payloads to achieve systemic effects
Scale virus production for commercialization
This year, over 100+ drug developers will converge at the OV Summit to disseminate the latest findings, build a comprehensive network of like-minded peers who share the same challenges and search for the latest combination and genetic engineering strategies.

Join the leading minds in oncolytic virus development to optimize the development of viral immunotherapies and improve patient outcomes in combination therapies.

HER2-Targeted Therapies Summit 2021
2021-06-22 - 2021-06-24 | Virtual Event
Welcome to the Digital HER2-Targeted Therapies Summit 2021 – The First Conference Focused on Exploring New Frontiers of HER2 as a Pan-Tumor Target
HER2 expressing patients are experiencing drug resistance, suboptimal duration of response and refractory/relapsed disease, stimulating new frontiers for HER2-targeted drug development. Impressive clinical data are being reported for next-generation anti-HER2 approaches in breast, gastric, lung, colon cancers and beyond. However, efforts to expand the clinical utility of HER2 as a pan-tumor target don’t stop there, with a flood of news on priority reviews, fast track approvals, IPOs and collaborations.
As such, the HER2-Targeted Therapies Digital Summit 2021 arrives as the first ever cross-disciplinary meeting for large pharma, biotech and academia, to maximize HER2-targeting in the pantumor setting. Expect to be involved in interactive discussions on the diversity of next generation anti-HER2 drugs in the clinic including ADCs, bispecifics, TKIs, CAR approaches & more.
This is your chance to overcome challenges of resistance against anti-HER2 approaches and accelerate therapies to patients in need. Examine HER2 heterogeneity across different tumors to maximize the commercial potential of this target. Discuss how quantitative pathology is helping to match HER2 expression with therapeutic response.
As the clinical and commercial growth potential of next generation HER2-targeted therapies becomes apparent, this is a timely and comprehensive forum giving you the opportunity to connect with leaders of the field directly.
Be part of this unique forum to strengthen your pipeline by expanding the clinical utility of your anti-HER2 candidate across tumor settings with the greatest unmet medical need.
To know more about HER2-Targeted Therapies Summit 2021 please click here.

CPhI & P-MEC China E-Trade Season- Sino-India Pharmaceutical Exchange
2021-06-22 15:00 - 19:00 (Asia/Shanghai) | Online
CPhI & P-MEC China has launched the “E-Trade Season 2021” from March to June 2021 to provide the pharmaceutical industry with online learning and trading opportunities. One of the themed sessions, named Sino-India Pharmaceutical Exchange, will be focusing on Indian & Chinese pharma markets, with online learning and trading opportunities.
The live stream webinar will look into policies, trends and practice, etc. of both Chinese and Indian pharma markets, covering topics including Development Trend of China’s API Industry and Cooperation Prospect with India, Requirements and Practical Procedures of Imported Drug Registration in China, and Development of Indian APIs and Generic Drugs in Indian and Chinese Market, with guest speakers from China Chamber of Commerce for Import & Export of Medicines & Health Products (CCCMHPIE), China Chinopharma Limited, and Dr. Reddy’s Laboratories.
The webinar is FREE for anyone to register and attend. Registered attendees will receive access to the webinar.

3rd Annual Blood-Brain Barrier Summit
2021-06-28 - 2021-06-30 | Online
Now in its 3rd year, the Blood-Brain Barrier Summit is the industry’s definitive blood-brain barrier conference, focused exclusively on evaluating innovative approaches to tackling the single biggest challenge for CNS drug developers.
Building on the success of last year’s meeting, this year’s program will uncover how leading companies and academics are working to enhance BBB penetration through the use of antibody therapies, nanoparticle engineering, AAV capsids, focused ultrasound, extracellular vesicles and more! New for this year we also explore the mechanisms of SARS-CoV-2 brain entry.
As we gather the best minds in this ever-challenging field, from the likes of AbbVie, Novartis, Roche, Merck and Ossianix, join this intimate forum to be part of the conversation focused on enhancing drug delivery across the blood-brain barrier and network and build meaningful partnerships with over 80 blood-brain barrier specialists.
To know more about 3rd Annual Blood-Brain Barrier Summit please click here.

6th Microbiome Movement - Drug Development Summit
2021-06-29 - 2021-07-01 | Virtual
Close the Clinical Gap, Discover the Next Generation of Microbiome-based Therapeutics, and Establish New Partnerships to Accelerate Your Research
The advancing scientific and clinical landscape mixed with the high-quality audience that we bring together has made this the must attend conference for those translating microbiome science into clinically successful therapeutics.
There is increased excitement around this years’ discussion; the community is now closer than ever to the first approved and commercially available microbiome-based therapeutic, key functions are beginning to be understood and the number of clinical candidates are increasing. However, there still remains an abundance of significant hurdles that must be overcome in order for continued success to be seen within the microbiome field. We are proud to bring together those at the forefront of tackling those challenges and is once again the centre of the 6th Microbiome Movement – Drug Development Summit.

The Microbiome Movement will provide the perfect opportunity for a collaborative approach between the biopharmaceutical and academic communities in order to pursue the causal role of the microbiome in disease and develop a new generation of microbiome-targeted therapeutics with predictable modes of action and consistent clinical outcomes.
From understanding microbiome functionality, leveraging lessons from clinical development and scaling manufacturing processes, through to leveraging microbiome biomarkers for patient stratification and diagnostics, our discussion will cover the latest scientific findings and industry updates from the end-to-end development of microbiome therapeutics.
There is still so much we can continue to do to make this complex science a clinical reality that improves the lives of patients, and we hope that you can join this years’ discussion to help towards the development of effective treatments across a range of indications and push microbiome products closer to commercialization.
To know more about 6th Microbiome Movement – Drug Development Summit please click here.

Induced Proximity-Based Drug Discovery Summit
2021-06-29 - 2021-07-01 | EST | Digital
Since the start of the 20th century, there have been three major waves of innovation in drug discovery. We are now at the start of a fourth wave, multispecific medicines, that will pave the way for new treatments aimed at thousands of disease targets currently viewed as “undruggable”. By inducing proximity between two or more proteins, multispecifics can harness the power of biology to go well beyond what conventional drugs can achieve.

As such, the inaugural Induced Proximity-Based Drug Discovery Summit arrives as the dedicated scientific and networking forum for large pharma, innovative biotech and research institutes to seize the endless potential of induced proximity- based drug discovery strategies to develop novel therapies for paradigm changing multispecific drugs of the future.
Join 100+ thought leaders of Chemically Biology, Screening Biology and Molecular Biology from the likes of Amgen, Ranok Therapeutics, Proxygen and more at the Induced Proximity- Based Drug Discovery Summit to advance your knowledge, differentiate your pipelines and be at the forefront of this new wave of innovation that will revolutionize drug discovery as currently known.
To know more about Induced Proximity-Based Drug Discovery Summit please click here.

JAK Inhibitors Drug Development Summit
2021-06-29 - 2021-07-01 | Virtual Event
Returning to the digital stage this summer, the 2nd JAK Inhibitors Drug Development Summit brings you the only dedicated JAK inhibitor conference that will allow you to utilize the knowledge of the greatest minds and thought leaders within the realms of the JAK pathway across dermatology, rheumatology, gastroenterology, oncology and hematology.
Focusing on optimized selectivity, drug-drug interactions, safety and efficacy challenges, this summit will give you the insight to successfully translate and develop the next generation of superior JAK inhibitors.
Ensure you attend this conference to learn, to network and to strengthen your pipeline, and implement the right clinical strategy.

3rd Cell Engager Summit
2021-06-30 - 2021-07-01 | Virtual Event
The 3rd Annual Cell Engager Summit is the only industry-led forum dedicated to developing multi-specific cell engaging therapies in liquid and solid tumor indications, accelerating early discovery innovation into the clinic.
This forum comes at a critical point for the cell engager field as the success observed in the hematological field has not been obtained with solid tumors yet. Preclinical and early clinical data for cell engagers targeting solid tumors have been hugely promising.
If you are part of a research team that is looking to accelerate the approval of cell engager therapies, then this conference has been curated with you in mind.
Below are a few highlights you won’t want to miss:

Drive efficacy in solid tumors with solid tumor targets addressed by Roche, Amgen, Pfizer, Merus, andCompass Therapeutics
Modulate the immune system to drive efficacy via co-stimulatory targets in solid tumors with Xencor, Harbour Biomed, Crescendo Biologics, Pieres,and Aptevo
Harness the power of the innate system for cell engagers and overcome the tumor microenvironment with Merck, Lava Therapeutics, Verseau Tx, andoNKo-Innate
Improving the therapeutic window of cell engagers – addressing toxicity, half-life, and CRS withAmunix, Synaffix, Revitope, and TeneoBio

To know more about 3rd Cell Engager Summit please click here.

ARDS Drug Development Summit 2021
2021-07-13 - 2021-07-15 | Virtual
The inaugural ARDS Drug Development Summit will bring 60+ biopharma leaders together to discover how the rise of SARS-CoV-2 ARDS, emergence of novel targets, and the past 12 months of unprecedented global focus on ARDS research has transformed this graveyard of drug development failures into a starting point for the next generation of therapeutics addressing not just ARDS, but broader, systemic inflammation.
Virtually uniting dedicated and experienced industry experts from Aqualung, Bone Therapeutics, Boehringer Ingelheim, Athersys and more, this trailblazing new meeting will help you overcome your most urgent drug development challenges.
